Dr. Hongyu Wang, M.D., Ph.D.
Assistant Professor, Center for Precision Biomedicine
Email Address: Hongyu.Wang@uth.tmc.edu
Phone Number: 713-500-3404
Room Number: SRB 330E
Narrative
Dr. Wang is an Assistant Professor in the Center for Proteomics and Systems Biology and Director of Clinical & Translational Proteomics Service Center and Co-Director of Molecular Diagnostics CLIA Laboratory. She received her M.D. from Southeast University, China and Ph.D. from University of Kiel, Germany where her work focused on transplantation immunology. She started her postdoctoral training at Baylor College of Medicine concentrated on hematopoietic stem cell differentiation and plasticity and gene therapy. Later, she extended her research in cancer immunotherapy and gene therapy for metastatic cancers. As a research scientist, she pursued her research works in broad fields, from cancer immunotherapy, autoimmune disease to aptamer technology based biomarker study at MD Anderson cancer Center, and UT Health IMM. She joined UT Health IMM in 2008 and became an assistant professor in 2016.
Research Interests
Dr. Wang’s current research interests include developing new generation aptamers for cell, tissue and proteomics based aptamer selection and targeted immunotherapy. A nanobead library of chemically-modified DNA aptamers will be used to simultaneously discover high affinity aptamer sequences and associated target proteins as biomarkers for diagnostics, imaging and therapies. Ultimately, the selected aptamers are going to be used as an alternate of antibodies for targeted immunotherapies.
| Selected peer-reviewed publications |
|---|
|
(13) Selection of PD1/PD-L1 X-Aptamers. Wang, H., Lam, C.H., Li, X., West, D.L., Yang, X., Biochimie, Volume 1632, Elsevier, 2017 https://doi.org/10.1016/j.biochi.2017.09.006 |
|
(12) Chapter 10: X-Aptamer Selection and Validation. Lokesh, G.L., Wang, H., Lam, C.H., Thiviyanathan, V., Ward, N., Gorenstein, D.G. and Volk, D.E. in RNA Nanostructures: Methods and Protocols, Eckart Bindewald and Bruce A. Shapiro (Eds), Methods in Molecular Biology, Volume 1632, pp 151-174, Elsevier, 2017; ISBN: 978-1-4939-7137-4 |
|
(11) Improving vascular maturation using non-coding RNAs increases anti-tumor effect of chemotherapy. *Mangala, L.S., *Wang, H., Jian, D., Wu, S.Y., Somasunderam, A., Volk, D.E., Lokesh, G.L.R., Li, X., Pradeep, S., Yang, X., Haemmerle, M., Rodriguez-Aguayo, C., Nagaraja, A.S., Rupaimoole, R., Bayraktar, E., Bayratktar, R., Li, L., Tanaka, T., Hu, W., Ivan, C., Gharpure, K.M., McGuire, M.H., Thiviyanathan, V., Zhang, X., Maiti, S.N., Bulayeva, N., Choi, H.-J., Dorniak, P.L., Cooper, L.J.N., Rosenblatt, K.P., Lopez-Berestein, G., Gorenstein, D.G., Sood, A.K. Journal of Clinical Investigation - Insights, 2016;1(17):e87754. doi:10.1172/jci.insight.87754. PMC5070952 (*equal contributions). |
|
(10) Morph-X-Select, a Morphologically-Based Aptamer Tissue Selection for Personalized Ovarian Cancer Biomarker Discovery. Wang, H., Li, X., Volk, D.E., Lokesh, G.L.-R., Elizondo-Riojas, M.-A., Li, L., Nick, A.M., Anil K. Sood, A.K., Rosenblatt, K.P., Gorenstein, D.G. Biotechniques, 61:249-259, 2016. |
|
(9) C3a receptor deficiency accelerates the onset of renal injury in the MRL/lpr mouse. Wenderfer SE, Wang H, Ke B, Wetsel RA, Braun MC. Mol Immunol. 2009 Apr; 46(7):1397-404.PMC PMC2697606 Free PDF |
|
(8) Gene-modified Bone Marrow Cell Therapy for Prostate Cancer. Wang H, Thompson TC. Gene Therapy 2008. May; 15(10):787-96. PubMed PMID: 18385769. |
|
(7) IL-12 Gene Modified Bone Marrow Cell Therapy Suppresses the Development of Experimental Metastatic Prostate Cancer. Wang H, Yang G, Timme TL, Fujita T, Naruishi K, Ji X, Brenner MK, Kadmon D, Thompson TC. Cancer Gene Ther. 2007 Oct; 14(10):819-27. PubMed PMID: 17627292. |
|
(6) Cooperative Effects of Adenoviral Vector-Mediated IL-12 Gene Therapy with Radiotherapy in a Preclinical Model of Metastatic Prostate Cancer. Fujita T, Timme TL, Tabata K, Naruishi K, Kusaka N, Watanabe M, Abdelfattah E, Zhu JX, Ren C, Ren C, Yang G, Goltsov A, Wang H, Vlachaki MT, Teh BS, Butler EB, Thompson TC. Gene Therapy; 2007 Feb; 14(3):227-36. PubMed PMID: 17024109. |
|
(5) Cytokine Gene Therapy for Genitourinary Cancer, in “Gene Therapy for Cancer" Timme TL, Fujita T, Wang H, Naruishi K, Kadmon D, Amato RJ, Miles BJ, Ayala G, Wheeler TM, Teh B, Butler B, Thompson TC., editor: Hunt KK, Totowa, N.J.: Humana Press, 2007. |
|
(4) Therapeutic Targets for Metastatic Prostate Cancer. Timme TL, Satoh T, Tahir SA, Wang H, Teh BS, Butler EB, Miles BJ, Amato RJ, Kadmon D, Thompson TC. Current Drug Targets, 2003, 4, 251-261. PMID: 12643475. |
|
(3) Disruption of the Caveolin-1 Gene Impairs Renal Calcium Reabsorption and Leads to Hypercalciuria and Urolithiasis. Cao G, Yang G, Timme TL, Saika T, Truong LD, Satoh T, Goltsov A, Park SH, Men T, Kusaka N, Tian W, Ren C, Wang H, Kadmon D, Cai WW, Chinault AC, Boone TB, Bradley A, Thompson TC. American Journal of Pathology, 2003, 162, 1241-1248. PMID: 12651616. PMC1851223 Free PDF |
|
(2) Regeneration of Ischemic Cardiac Muscle and Vascular Endothelium by Adult Stem Cells. Jackson KJ, Majka S, Wang H, Pocius J, Hartley C, Majeski M, Entman M, Lloyd M, Hirschi K, and Goodell MA. Journal of Clinical Investigation, 2001, 107, 1395-1402. PMID: 11390421. PMC209322 Free PDF |
|
(1) Stem Cell Plasticity in Muscle and Bone Marrow. Goodell MA, Jackson KJ, Majka SM, Mi T, Wang H, Pocius J, Hartley CJ, Majeski MW, Entman ML, Michael LH, and Hirshci KK. Annals of the New York Academy of Sciences, 2001, 938, 208-218. PMID: 11458510. |
